Patent search ap:"GILEAD SCIENCES Page INC."

31.

发明公开
COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS 审中-公开

公开(公告)号：US20240091251A1

公开(公告)日：2024-03-21

申请号：US18241303

申请日：2023-09-01

Applicant: Gilead Sciences, Inc.

Inventor： Nate Larson , Robert G. Strickley

IPC: A61K31/724 , A61K9/00 , A61K9/19 , A61K31/683 , A61K47/40 , A61K47/69 , A61P31/12

CPC classification number: A61K31/724 , A61K9/0019 , A61K9/19 , A61K31/683 , A61K47/40 , A61K47/6951 , A61P31/12

Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

32.

发明授权
Combination MCL-1 inhibitors with anti-body drug conjugates 有权

公开(公告)号：US11931424B2

公开(公告)日：2024-03-19

申请号：US17836480

申请日：2022-06-09

Applicant: Gilead Sciences, Inc.

Inventor： Thomas F. Kenney , Clinton K. Matson , Chandrasekar Venkataramani

IPC: A61K47/68 , A61K31/519 , A61K31/553 , A61P11/00 , A61P35/00 , A61P35/04

CPC classification number: A61K47/6851 , A61K31/519 , A61K31/553 , A61K47/6803 , A61P11/00 , A61P35/00 , A61P35/04

Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.

33.

发明授权
Compounds and methods for treatment of viral infections 有权

公开(公告)号：US11926645B2

公开(公告)日：2024-03-12

申请号：US17458023

申请日：2021-08-26

Applicant: Gilead Sciences, Inc.

Inventor： Elaine Bunyan , Byoung-Kwon Chun , Kassibla E. Dempah , Hon C. Hui , Rao V. Kalla , Richard L. Mackman

IPC: C07H7/06 , A61P31/12

CPC classification number: C07H7/06 , A61P31/12 , C07B2200/13

Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

34.

发明授权
Diacylglyercol kinase modulating compounds 有权

公开(公告)号：US11926628B2

公开(公告)日：2024-03-12

申请号：US17844871

申请日：2022-06-21

Applicant: Gilead Sciences, Inc.

Inventor： Julian A. Codelli , Michael Graupe , Juan A. Guerrero , Jesse M. Jacobsen , Tetsuya Kobayashi , Jonathan William Medley , Yasamin Moazami , Leena B. Patel , Jie Xu , Suet C. Yeung

IPC: C07D471/14 , A61K31/519

CPC classification number: C07D471/14

Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

35.

外观设计
Pharmaceutical package 有权

公开(公告)号：USD1016608S1

公开(公告)日：2024-03-05

申请号：US29837856

申请日：2022-05-09

Applicant: Gilead Sciences, Inc.

Designer： Benjamin Luke Kozub , Brian Nilstoft , Kevin Nguyen , James Paul Oberhauser , Roman Shumylo , Joseph Anthony Cordova , Jinhui Yun , William Harold Lizor, Jr. , Adam Hilborn , Jesse Arnold Fourt , Léo Boris Marzolf , Pratap Uday Ganapathy , Brooke Genelle Thyng , Caricia Catalani , Soizic Porhel , Jose Angel Meza , Steven M. Scally , Mary Cassandra Lodwick

Abstract: FIG. 1 is a front top perspective view of a pharmaceutical package in an open configuration;
FIG. 2 is a back bottom perspective view thereof;
FIG. 3 is front view thereof;
FIG. 4 is a back view thereof;
FIG. 5 is left side view thereof;
FIG. 6 is right side view thereof;
FIG. 7 is top view thereof;
FIG. 8 is bottom view thereof;
FIG. 9 is a front top perspective view of the pharmaceutical package in a partially folded configuration;
FIG. 10 is a back bottom perspective view thereof;
FIG. 11 is front view thereof;
FIG. 12 is a back view thereof;
FIG. 13 is left side view thereof;
FIG. 14 is right side view thereof;
FIG. 15 is top view thereof;
FIG. 16 is bottom view thereof;
FIG. 17 is a front bottom perspective view of the pharmaceutical package in a fully folded configuration;
FIG. 18 is a back top perspective view thereof;
FIG. 19 is left side view thereof;
FIG. 20 is a right side view thereof;
FIG. 21 is front view thereof;
FIG. 22 is back view thereof;
FIG. 23 is top view thereof; and,
FIG. 24 is bottom view thereof.
The dashed lines in the drawings depict portions of the pharmaceutical package that form no part of the claimed design. The dot-dash lines in the drawings depict the boundaries of the claim and form no part thereof.
The gray shading in the figures depicts a contrast of appearance.

36.

发明公开
METHODS OF TREATING NASH 审中-公开

公开(公告)号：US20240066016A1

公开(公告)日：2024-02-29

申请号：US18372242

申请日：2023-09-25

Applicant: Gilead Sciences, Inc.

Inventor： David G. Breckenridge , Grant R. Budas , Ruchi Gupta , James G. Taylor , Matthew R. Warr , Nathan E. Wright

IPC: A61K31/4709 , A61K31/519 , A61P1/16 , A61P3/04

CPC classification number: A61K31/4709 , A61K31/519 , A61P1/16 , A61P3/04

Abstract: The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

37.

发明授权
Cot modulators and methods of use thereof 有权

公开(公告)号：US11905299B2

公开(公告)日：2024-02-20

申请号：US17317041

申请日：2021-05-11

Applicant: Gilead Sciences, Inc.

Inventor： Elizabeth M. Bacon , Gayatri Balan , Chien-Hung Chou , Christopher T. Clark , Jeromy J. Cottell , Musong Kim , Thorsten A. Kirschberg , John O. Link , Gary Phillips , Scott D. Schroeder , Neil H. Squires , Kirk L. Stevens , James G. Taylor , William J. Watkins , Nathan E. Wright , Sheila M. Zipfel

IPC: C07D401/12 , C07D498/04 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D401/14 , C07B59/00

CPC classification number: C07D498/04 , C07B59/002 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07B2200/05

Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

38.

发明授权
Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections 有权

公开(公告)号：US11883397B2

公开(公告)日：2024-01-30

申请号：US17532148

申请日：2021-11-22

Applicant: Gilead Sciences, Inc.

Inventor： Manoj C. Desai , Mingzhe Ji , Haolun Jin , Hyung-Jung Pyun , Teresa Alejandra Trejo Martin

IPC: A61K31/4985 , C07D487/22 , C07D471/18 , C07D471/14

CPC classification number: A61K31/4985 , C07D471/14 , C07D471/18

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):

including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

39.

发明公开
PHOSPHOLIPID COMPOUNDS AND USES THEREOF 审中-公开

公开(公告)号：US20240025932A1

公开(公告)日：2024-01-25

申请号：US18332587

申请日：2023-06-09

Applicant: Gilead Sciences, Inc.

Inventor： Scott E. Lazerwith , Jonathan William Medley , Philip A. Morganelli , Devan Naduthambi , Thomas P. Stratton , Peiyuan Wang

IPC: C07F9/6561 , A61P31/12

CPC classification number: C07F9/6561 , A61P31/12

Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.